



Erratum to the association between the ERCC1/2 polymorphisms and radiotherapy efficacy in 87 patients with non-small cell lung cancer

Editorial Office

Journal of Thoracic Disease

Correspondence to: Editorial Office, Journal of Thoracic Disease. Email: jtd@amepc.org.

Submitted Feb 07, 2022. Accepted for publication Feb 18, 2022.

doi: 10.21037/jtd-2022-02

View this article at: <https://dx.doi.org/10.21037/jtd-2022-02>

Erratum to: J Thorac Dis 2021;13:3126-36

In the article (1) titled “the association between the ERCC1/2 polymorphisms and radiotherapy efficacy in 87 patients with non-small cell lung cancer” published in *Journal of Thoracic Disease* (J Thorac Dis 2021;13:3126-36. doi: 10.21037/jtd-21-755), there were some errors in the Results section.

(I) There is a typo in a confidence interval (CI) value.

Original sentence: The median PFS of patients with the G allele was 18.9 months (95% CI: 13.960–24.780), which was significantly higher than that of patients with the A allele (11.3 months, 95% CI: 8.655–14.005); the difference between the two groups was statistically significant (P=0.040).

Corrected sentence: The median PFS of patients with the G allele was 18.9 months (95% CI: 13.960–23.780), which was significantly higher than that of patients with the A allele (11.3 months, 95% CI: 8.655–14.005); the difference between the two groups was statistically significant (P=0.040).

(II) There were errors in *Table 3*. The corrected version of *Table 3* is included below.

Table 3 Association between the ERCC1/2 gene polymorphisms and prognosis in 87 NSCLC patients who received definitive radiotherapy

Gene	MST (months)	95% CI	P	Median PFS (months)	95% CI	P
<i>rs11615</i>						
AA	6.77	0–14.05	0.000	5.13	0–15.13	0.019
AG	19.77	11.14–28.40		11.33	5.76–16.91	
GG	30.90	12.83–48.97		18.87	13.96–23.78	
A allele	16.17	9.10–23.24	0.003	11.33	8.66–14.01	0.040
G allele	30.90	12.83–48.97		18.87	13.96–23.78	
<i>rs3212961</i>						
GG	24.77	4.75–44.79	0.735	11.53	6.41–16.66	0.910
GT	23.97	15.75–32.19		18.07	12.67–23.47	
TT	24.93	9.37–40.49		11.60	5.28–17.92	

Table 3 (continued)

Table 3 (continued)

Gene	MST (months)	95% CI	P	Median PFS (months)	95% CI	P
<i>G allele</i>	24.93	18.95–30.91	0.441	16.17	11.84–20.50	0.897
<i>T allele</i>	24.77	4.75–44.79		11.53	6.41–16.66	
<i>rs3212986</i>						
AA	71.13	0–160.416	0.092	15.53	0–38.01	0.718
AC	29.10	18.92–39.28		18.70	11.91–25.49	
CC	21.53	12.97–30.09		14.67	8.85–20.49	
<i>A allele</i>	30.90	15.68–46.12	0.086	18.07	8.85–20.49	0.423
<i>C allele</i>	21.53	12.97–30.09		14.67	11.89–24.25	
<i>rs13181</i>						
TT	24.93	16.19–33.67	0.692	14.67	10.17–19.17	0.921
TG	24.77	12.67–36.87		19.07	9.96–28.19	
<i>rs238406</i>						
TT	16.17	0–36.26	0.686	11.33	8.92–13.74	0.143
TG	28.67	22.72–34.62		21.50	16.86–26.14	
GG	19.80	13.76–25.84		11.30	6.67–15.93	
<i>T allele</i>	26.83	21.44–32.22	0.562	16.83	12.16–21.50	0.097
<i>G allele</i>	19.80	13.76–25.84		11.30	6.67–15.93	
<i>rs1799793</i>						
CC	25.40	18.74–32.05	0.222	15.53	11.79–19.27	0.411
CT	19.07	10.48–27.66		16.13	2.89–29.37	

NSCLC, non-small cell lung cancer; CI, confidence interval; MST, median overall survival time; PFS, progression-free survival.

Click [here](#) to view the updated version of the article.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

- Jiang C, Guo Y, Li Y, et al. The association between the ERCC1/2 polymorphisms and radiotherapy efficacy in 87 patients with non-small cell lung cancer. *J Thorac Dis* 2021;13:3126-36.

Cite this article as: Editorial Office. Erratum to the association between the ERCC1/2 polymorphisms and radiotherapy efficacy in 87 patients with non-small cell lung cancer. *J Thorac Dis* 2022;14(3):797-798. doi: 10.21037/jtd-2022-02